Report on an investigational cannabidiol therapy reaching the clinical site to support trial start for chemotherapy-induced peripheral neuropathy.
Key Takeaways
- Investigational product manufactured in 2025 was delivered to the University of Edinburgh pharmacy
- ACTiON Phase 2 trial is double-blind, placebo-controlled, crossover with a 92 participant target
- Trial is led by Professor Marie Fallon and funded by an NIHR EME grant